# A Study of Picankibart in Patients With Active Psoriatic Arthritis

> **NCT07295509** · PHASE2,PHASE3 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 222 (estimated)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **OTHER:** Placebo
- **DRUG:** Picankibart

## Key facts

- **NCT ID:** NCT07295509
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07295509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07295509, "A Study of Picankibart in Patients With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07295509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*